MOLN vs. KPTI, OMGA, ADVM, KOD, BTAI, ADPT, CABA, ALEC, VYGR, and TCRX
Should you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Karyopharm Therapeutics (KPTI), Omega Therapeutics (OMGA), Adverum Biotechnologies (ADVM), Kodiak Sciences (KOD), BioXcel Therapeutics (BTAI), Adaptive Biotechnologies (ADPT), Cabaletta Bio (CABA), Alector (ALEC), Voyager Therapeutics (VYGR), and TScan Therapeutics (TCRX). These companies are all part of the "medical" sector.
Molecular Partners (NASDAQ:MOLN) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking and institutional ownership.
Karyopharm Therapeutics has a net margin of -104.18% compared to Molecular Partners' net margin of -864.64%. Karyopharm Therapeutics' return on equity of 0.00% beat Molecular Partners' return on equity.
Molecular Partners has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500.
26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 5.9% of Molecular Partners shares are held by company insiders. Comparatively, 4.3% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Karyopharm Therapeutics received 515 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 72.05% of users gave Karyopharm Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Molecular Partners currently has a consensus price target of $4.50, indicating a potential upside of 25.00%. Karyopharm Therapeutics has a consensus price target of $4.80, indicating a potential upside of 395.30%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Molecular Partners.
Molecular Partners has higher earnings, but lower revenue than Karyopharm Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Karyopharm Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Karyopharm Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.94 beat Karyopharm Therapeutics' score of 0.62 indicating that Molecular Partners is being referred to more favorably in the media.
Summary
Karyopharm Therapeutics beats Molecular Partners on 12 of the 18 factors compared between the two stocks.
Get Molecular Partners News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Molecular Partners Competitors List
Related Companies and Tools
